By Rory McCann, Marketing Manager & Conference Producer, LSN
Stephanie Marrus, Managing Director of Entrepreneurship at the University of California San Francisco (UCSF) is on a mission, one that’s been decades in the making. Starting in marketing, business development, and growing into company leadership and entrepreneurship, Stephanie has built an impressive career that sets her up to effectively train scientific startup founders to succeed. In the age of Covid, she’s taken her show on the virtual road and has impacted hundreds of entrepreneurs globally.
Life Science Nation is proud to host Stephanie and the UCSF Innovation Ventures and Entrepreneurship Program at RESI Partnering Week, September 13-17. Get to know Stephanie and the UCSF Innovation Ventures and Entrepreneurship Program in a recent interview and get started on your entrepreneurial journey with Digital RESI and UCSF! Enrollment is open until Friday, September 17. The next class takes place Wednesday, September 29. Sign up today!
By Karen Deyo, Director of Investor Research, Israel BD, LSN
Life Science Nation’s (LSN) virtual events continue to be successful with a global gathering of early-stage startups, as well as the investors and strategic partners looking to invest in them. With attendees representing over 30 countries from 5 continents participating in this week’s Redefining Early Stage Investment (RESI), more than 1500 meetings were booked over the three days of the conference. Individual companies booked up to 40 meetings over the course of the conference, with more than 75% of meetings booked occurring between companies and investors.
In addition to an extremely active partnering platform, the panels, workshops and pitch sessions were well-attended and dynamic, with enthusiastic audience participation. RESI events continue to show that even in an all virtual platform, the needle keeps moving forward in the life sciences, bringing life-saving technologies closer and closer to market.
By Rory McCann, Marketing Manager & Conference Producer, LSN
A question not asked enough by early-stage startup founders when looking for banking options is, “Which available resources are specific to the needs of my company and industry?” In a recent conversation with First Republic Bank’s Nishta Rao, we discussed this question, why it isn’t asked enough, and what founders stand to gain when they understand how much more valuable a banking relationship can be when it’s the right fit. We discuss First Republic’s life science toolkit and the resources available to early-stage startups in life science and healthcare.
Listen to our conversation and get to know First Republic Bank at RESI Partnering Week, September 13-15. Sign up today and mark your calendar for the sessions answering your questions about what a powerful banking relationship can do for you.
Tuesday, September 14 | 11 AM EDT
Beyond Banking: Finding the Right Financial Partner for You
Nishta Rao, Managing Director, Life Science, First Republic Bank
Dennis Ford, CEO, Life Science Nation
When your startup firm gains traction, you will inevitably need a bank that can add value and understand your distinct early-stage entrepreneurial needs. There are an array of financial institutions that have programs in the life science market to aid and guide early-stage entrepreneurs to set up the right financial packages. First Republic Bank is a leader in the early-stage life science market with decades of experience and dedicated teams that provide support to scientist entrepreneurs. In this fireside chat, we discuss the programs and services available for startups and how to engage and take advantage of the FRB offerings to help your business grow.
Wednesday, September 15 | 3 PM EDT
How to Evaluate Your Banking Partner Workshop
Nishta Rao, Managing Director, Life Science, First Republic Bank
Life Science companies need more from a bank than just accounts and transactions. The right banking partner brings a mix of excellent service, industry expertise, and the ability to help companies grow. Join Nishta Rao of First Republic Bank to hear what companies should be looking for in a sound banking partner.
By Karen Deyo, Director of Investor Research, Israel BD, LSN
RESI Partnering Week, September 13-17, launches next week and featuring a star-studded lineup of panel discussions, live pitch sessions, educational workshops, fireside chats, and partnering. Check out our lineup of pre-recorded content, as well as the schedule of live events across Digital RESI September, RESI AI, and RESI Longevity.
If you haven’t yet signed up to start booking meetings and connecting with investors who are a fit for your product and stage of development, there is still time. Sign up today!
Digital RESI (September 13-15)
Monday (9/13)
Tuesday (9/14)
Wednesday (9/15)
9:00 EDT
Company Valuation for Fundraising Workshop
10:00 EDT
Medical Devices Panel
Asia Cross-Border Panel
Corporate VC Panel
11:00 EDT
IPC Session 1: Therapeutics
Beyond Banking: Finding the Right Financial Partner for You
Negotiating Term Sheets Workshop
12:00 EDT
Seed Funds Panel
Tales from the Road Panel
Angels & Family Offices Panel
13:00 EDT
IPC Session 2: Diagnostics
UCSF Innovation Ventures and Entrepreneurship Program Workshop
Financing Scientific Instrumentation as a Startup Company Workshop
700+ investors representing VC, Corporate VC, Big Pharma, Angels, Family Offices, and more are meeting virtually across RESI Partnering Week, September 13-17. There is still time to sign up and start booking meetings. The RESI partnering platform is enabled to narrow down searches for investors who are a fit for your product, stage of development, and specific needs unique to your company. Check out the firms attending this week and select the conference you’re interested in to see the firms participating.
The Pharma is a global pharmaceutical company, with headquarters in Japan and USA offices on the East Coast. The Pharma focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the Pharma is actively seeking novel and innovative therapeutic opportunities for in-licensing in CNS and nephrology. In addition, the firm manages an early-stage investment fund (currently $30M) that actively invests in global early-stage opportunities that fit the firm’s areas of interest.
The Pharma is interested in innovative therapeutics that address areas of significant unmet need in CNS and renal diseases. The Pharma is a global leader in CNS, both neurology and psychiatry, opportunistic to all types of indications, both symptomatic and disease-modifying. In nephrology, the firm is particularly interested in novel mechanism addressing both acute and chronic kidney diseases of tubular and glomerular origin, as well as associated inflammatory and fibrotic mechanisms. The firm will consider both clinical and pre-clinical compounds with compelling biological valid proof-of-concept.
The Pharma has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm aims to obtain global commercial rights as a preferential end-goal.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
Life Science Nation (LSN) is pleased to announce the Innovator’s Pitch Challenge (IPC) finalists who will be presenting at the upcoming RESI Partnering Week, September 13-17. The IPC continues to see a record number of applicants, establishing itself as a differentiated and effective platform to showcase innovative technologies during a virtual conference age.
Each participating company will have a dedicated landing page with their pitch video and supplementary materials and will participate in a live Q&A session with investors and industry experts providing feedback and questions, which will help companies better prepare for future investor meetings, understand investor perspectives, and enhance their visibility and network. Many past participants have credited the IPC to unexpected follow-up meetings and new connections.
RESI Partnering Week attendees do not want to miss out on these engaging sessions! If you are not registered, it is not too late – you can register here. If you are an active investor interested in getting involved with these sessions, please reach out to research@lifesciencenation.com for more information.
Below are the participating companies – please click on their logos to learn more!
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Next Phase Newsletter 